CD274 and non-small cell lung carcinoma: Nevertheless, consistent with our findings, several studies have reported an association between PD-L1 TPS ≥ 90% and improved outcomes in metastatic NSCLC patients receiving first-line pembrolizumab monotherapy compared to those with PD-L1 TPS 50–89% in terms of mPFS and mOS [38,39,40].